Sort   by:  
 Page size 
UnknownSoluble Klotho: a possible predictor of quality of life in acromegaly patients.

Purpose

Although quality of life (QoL) is improved in patients with acromegaly after disease control, QoL correlates only weakly with traditional biomarkers. Our objective is to investigate a potential relation between the new serum biomarker soluble Klotho (sKlotho), GH and insulin-like gro...
S-EPMC7343750 | biostudies-literature
UnknownMore than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.

Objective

To report the final long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY.

Design

Global (15 countries), multicentre, non-interventional study (2004-2017).

Methods

The complete ACROSTUDY cohort comprised patient...
S-EPMC8428076 | biostudies-literature
UnknownUnacylated ghrelin suppresses ghrelin-induced neuronal activity in the hypothalamus and brainstem of male rats [corrected].
Ghrelin, the endogenous growth hormone secretagogue, has an important role in metabolic homeostasis. It exists in two major molecular forms: acylated (AG) and unacylated (UAG). Many studies suggest different roles for these two forms of ghrelin in energy balance regulation. In the present study, we ...
S-EPMC4031147 | biostudies-literature
UnknownTransition readiness among adolescents with rare endocrine conditions.

Objective

Adolescents and young adults (AYA) with common endocrine disorders show a high dropout (up to 50%) after the transfer from paediatric to adult endocrinology. Little is known about transition readiness in rare endocrine conditions (rEC). This study aims to assess medical self-manage...
S-EPMC8111322 | biostudies-literature
UnknownLanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.

Objective

To evaluate extended dosing intervals (EDIs) with lanreotide Autogel 120 mg in patients with acromegaly previously biochemically controlled with octreotide LAR 10 or 20 mg.

Design and methods

Patients with acromegaly had received octreotide LAR 10 or 20 mg/4 weeks for ≥ 6 mo...
S-EPMC4544680 | biostudies-literature
UnknownEffects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.

Purpose

To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data.

Methods

PRIMARYS was a 1-year, open-label study of lanreotide Autogel (Depot in USA) 120 mg every 4 weeks in 90 treatment-naïve patients wi...
S-EPMC4799252 | biostudies-literature
UnknownPasireotide versus octreotide in acromegaly: a head-to-head superiority study.

Context

Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control.

Objective

Our objective was to d...
S-EPMC3965714 | biostudies-literature
UnknownNeuroimaging Findings in US Government Personnel and Their Family Members Involved in Anomalous Health Incidents.

Importance

US government personnel stationed internationally have reported anomalous health incidents (AHIs), with some individuals experiencing persistent debilitating symptoms.

Objective

To assess the potential presence of magnetic resonance imaging (MRI)-detectable brain lesions in...
S-EPMC10949155 | biostudies-literature
UnknownGhrelin.

Background

The gastrointestinal peptide hormone ghrelin was discovered in 1999 as the endogenous ligand of the growth hormone secretagogue receptor. Increasing evidence supports more complicated and nuanced roles for the hormone, which go beyond the regulation of systemic energy metabolism.<...
S-EPMC4443295 | biostudies-literature
UnknownClinical, Biomarker, and Research Tests Among US Government Personnel and Their Family Members Involved in Anomalous Health Incidents.

Importance

Since 2015, US government and related personnel have reported dizziness, pain, visual problems, and cognitive dysfunction after experiencing intrusive sounds and head pressure. The US government has labeled these anomalous health incidents (AHIs).

Objective

To assess whethe...
S-EPMC10949151 | biostudies-literature
Sort   by:  
 Page size